Gold Reserve Provides Update on Adjournment of August 18, 2025 Sale Hearing
The Court stated its rationale for the adjournment as follows:
The Court reaches this conclusion reluctantly, but in the face of the following realities: a Sale Hearing held on August 18 would be directed to evaluating whether to accept the Special Master's recommendation to approve the Dalinar Energy bid, but the Special Master has recently received an unsolicited bid he is currently evaluating and which he may determine is a "Superior Proposal" to Dalinar's (as defined in the Dalinar SPA); if the Special Master determines he has received a Superior Proposal, Dalinar is entitled to time to match it; although all discovery undertaken and briefing received to date is directed to the Dalinar bid, there is some possibility the Special Master may no longer be recommending approval of that bid, which could render a Sale Hearing focused on the Dalinar bid unnecessary. While Gold Reserve may be correct that the unsolicited bid presently being evaluated is "a non-actionable underbid" (O.I. 2050 at 2) (emphasis omitted), the Court is not able to make a determination on this point in time to go forward with a Sale Hearing four days from now, especially since the Special Master has not yet completed his evaluation of the unsolicited bid.
The Court stated its 'inclinations as to appropriate next steps' as follows:
At this time, the Court's inclinations as to the appropriate next steps are to: (i) order the Special Master to determine, no later than August 25, whether he is adhering to his recommendation of the Dalinar bid or, instead, has received a Superior Proposal; (ii) order the Special Master to submit, no later than August 29, a proposed schedule for additional limited discovery, if any, necessitated by whatever decision he has made by August 25 and any additional, streamlined briefing; (iii) reschedule the Sale Hearing for some or all of the following dates: September 15-18, October 20-23; (iv) require any entity intending to participate in the Sale Hearing to request a specific, total number of hours it will use at the hearing for its examination of witnesses and argument (to include opening statements and closing arguments); and (v) provide a schedule and page limits for expedited post-hearing briefing and submission of proposed findings of fact.
The Court summarized its Order, and requested further briefing from the Special Master and parties on the foregoing inclinations, as follows:
ORDER: The Sale Hearing is CONTINUED to a date to be determined by separate order, after the Court receives additional input from the Special Master, Sale Process Parties, Additional Judgment Creditors, and any other interested entity. IT IS FURTHER ORDERED that the Saturday, August 16 deadline for sur-replies in response to pending objections is VACATED. The Court will hold an in-person hearing on Monday, August 18, at 10:00 a.m. at the J. Caleb Boggs Federal Building, Courtroom 2A. The hearing is not an evidentiary hearing and all witnesses who were planning to testify are excused from appearing in Wilmington next week. The Special Master and Sale Process Parties shall, and any Additional Judgment Creditor or other interested entity may, (i) file opening briefs regarding the above inclinations, not to exceed 5 pages, no later than Saturday, August 16, at 12:00 p.m., and (ii) file response briefs, not to exceed 3 pages, no later than Sunday, August 17, at 5:00 p.m.
A copy of the Court's Order, the adjournment request, and the Company's opposition to the adjournment request will be posted shortly here.
A complete description of the Delaware sale proceedings can be found on the Public Access to Court Electronic Records system in Crystallex International Corporation v. Bolivarian Republic of Venezuela, 1:17-mc-00151-LPS (D. Del.) and its related proceedings.
Cautionary Statement Regarding Forward-Looking statements
This release contains 'forward-looking statements' within the meaning of applicable U.S. federal securities laws and 'forward-looking information' within the meaning of applicable Canadian provincial and territorial securities laws and state Gold Reserve's and its management's intentions, hopes, beliefs, expectations or predictions for the future. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management at this time, are inherently subject to significant business, economic and competitive uncertainties and contingencies. They are frequently characterized by words such as "anticipates", "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed", "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements contained in this press release include, but are not limited to, statements relating to any bid submitted by the Company for the purchase of the PDVH shares (the 'Bid').
We caution that such forward-looking statements involve known and unknown risks, uncertainties and other risks that may cause the actual events, outcomes or results of Gold Reserve to be materially different from our estimated outcomes, results, performance, or achievements expressed or implied by those forward-looking statements, including but not limited to: the discretion of the Special Master to consider the Bid, to enter into any discussions or negotiation with respect thereto; the Bid will not be approved by the Court as the 'Final Recommend Bid' under the Bidding Procedures, and if approved by the Court may not close, including as a result of not obtaining necessary regulatory approvals, including but not limited to any necessary approvals from the U.S. Office of Foreign Asset Control ('OFAC'), the U.S. Committee on Foreign Investment in the United States, the U.S. Federal Trade Commission or the TSX Venture Exchange; failure of the Company or any other party to obtain sufficient equity and/or debt financing or any required shareholders approvals for, or satisfy other conditions to effect, any transaction resulting from the Bid; that the Company may forfeit any cash amount deposit made due to failing to complete the Bid or otherwise; that the making of the Bid or any transaction resulting therefrom may involve unexpected costs, liabilities or delays; that, prior to or as a result of the completion of any transaction contemplated by the Bid, the business of the Company may experience significant disruptions due to transaction related uncertainty, industry conditions, tariff wars or other factors; the ability to enforce the writ of attachment granted to the Company; the timing set for various reports and/or other matters with respect to the Sale Process may not be met; the ability of the Company to otherwise participate in the Sale Process (and related costs associated therewith) ; the amount, if any, of proceeds associated with the Sale Process; the competing claims of other creditors of Venezuela, PDVSA and the Company, including any interest on such creditors' judgements and any priority afforded thereto; uncertainties with respect to possible settlements between Venezuela and other creditors and the impact of any such settlements on the amount of funds that may be available under the Sale Process; and the proceeds from the Sale Process may not be sufficient to satisfy the amounts outstanding under the Company's September 2014 arbitral award and/or corresponding November 15, 2015 U.S. judgement in full; and the ramifications of bankruptcy with respect to the Sale Process and/or the Company's claims, including as a result of the priority of other claims. This list is not exhaustive of the factors that may affect any of the Company's forward-looking statements. For a more detailed discussion of the risk factors affecting the Company's business, see the Company's Management's Discussion & Analysis for the year ended December 31, 2024 and other reports that have been filed on SEDAR+ and are available under the Company's profile at www.sedarplus.ca.
Investors are cautioned not to put undue reliance on forward-looking statements. All subsequent written and oral forward-looking statements attributable to Gold Reserve or persons acting on its behalf are expressly qualified in their entirety by this notice. Gold Reserve disclaims any intent or obligation to update publicly or otherwise revise any forward-looking statements or the foregoing list of assumptions or factors, whether as a result of new information, future events or otherwise, subject to its disclosure obligations under applicable rules promulgated by applicable Canadian provincial and territorial securities laws.
For further information regarding Dalinar Energy, visit: https://www.dalinarenergy.com.
For further information regarding Gold Reserve Ltd., visit https://www.goldreserve.bm.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
an hour ago
- CBC
Union says 'nothing scheduled' with Air Canada as strike by flight attendants halts operations
Social Sharing The union representing Air Canada flight attendants says no talks are scheduled with the airline as a strike that began early Saturday led to the airline suspending operations. The union and airline met late Friday night before 10,000 flight attendants walked off the job at 12:58 a.m. ET, Wesley Lesosky, president of the Air Canada component of the Canadian Union of Public Employees (CUPE), told a morning news conference. Lesosky said their last meeting was Friday night, but Air Canada offered "nothing of substance" to bring back to members. Asked when Canadians could expect to be back on flights, Lesosky said it's up to Air Canada, but that public pressure on the airline will make a "huge difference" in reaching a settlement. CBC News has reached out to Air Canada for comment and will update this story with any response. Jobs Minister Patty Hajdu also met with both the airline and union on Friday night. "It is unacceptable that such little progress has been made. Canadians are counting on both parties to put forward their best efforts," Hajdu said on social media platform X. Picket lines set up across Canada All Air Canada and Air Canada Rouge flights are suspended for now. Around 130,000 customers will be affected each day the strike continues, said the airline. Flights by Air Canada Express, which are operated by third-party airlines Jazz and PAL, are not affected. Cross Country Checkup is asking: How have you been affected by the Air Canada strike? What should be done about it? Leave your comment here and we may read it or call you back for our show on Sunday. "Air Canada deeply regrets the effect the strike is having on customers," it said in a brief statement early Saturday morning. CUPE has set up picket lines at airports across Canada, including in Montreal, Toronto, Calgary and Vancouver. Striking flight attendants also plan to picket at airports in Halifax, Ottawa and Winnipeg. In the meantime, passengers around the world are feeling the effects of the flight attendants' strike. Keelin Pringnitz and her family are from Ottawa and were returning from a European vacation, but were left stranded after flights were cancelled. "It was an end of my maternity leave kind of trip. We went to the Faroe Islands and Norway, travelling through Air Canada to London," Pringnitz said from London's Heathrow Airport. She noted there was an option for travellers to go the U.S. but she and others were told there wouldn't be any further assistance once they landed in the U.S. "It didn't go over well with the line. Nobody really seemed interested, everybody seemed a little bit amused almost at the suggestion, or exasperated, because it is a bit ridiculous to offer to take stranded passengers to a different country to strand them there." For customers due to travel soon whose flights are not yet cancelled, Air Canada said it will allow them to rebook their travel or obtain a credit for future travel. Sides at an impasse on pay Air Canada and CUPE have been in contract talks for about eight months, but have yet to reach a tentative deal. Both sides say they remain far apart on the issue of pay and the unpaid work flight attendants do when planes aren't in the air. WATCH | Thousands of Air Canada flight attendants walk off the job: Air Canada strike begins as flight attendants walk off the job 2 hours ago More than 10,000 Air Canada flight attendants went on strike early Saturday morning, after the airline and the union representing them failed to reach a deal ahead of the deadline. With a work stoppage now in effect, Air Canada estimates that 130,000 customers will be affected each day of a strike, a figure that includes 25,000 Canadian travellers who are abroad. The airline's latest offer included a 38 per cent increase in total compensation, including benefits and pensions over four years, that it said "would have made our flight attendants the best compensated in Canada." But the union pushed back, saying the proposed 8 per cent raise in the first year didn't go far enough because of inflation. Government intervention Air Canada previously asked Hajdu to intervene by ordering the parties to enter a binding arbitration process — a power granted to the minister through Sec. 107 of the Canada Labour Code. On Friday, Hajdu urged Air Canada and the union to get back to the negotiating table, suggesting she's not ready to intervene. The minister said the union has indicated many of its demands have been met, suggesting there is a path forward to a deal. WATCH | The impact of the flight attendants' strike on travellers: Air Canada flight attendants strike, setting stage for travel chaos 10 hours ago Canada's largest airline is now mostly grounded after a strike deadline passed for more than 10,000 Air Canada flight attendants. Hundreds of flights have been cancelled impacting over 100,000 travellers and leaving some stranded. Hajdu had asked the union to respond to the company's request. CUPE indicated Friday it opposed arbitration, instead maintaining its desire to solve the impasse through bargaining.
Globe and Mail
an hour ago
- Globe and Mail
2 Top Dividend Stocks to Buy on the Dip
Key Points Pfizer's pipeline in oncology, combined with its cost-cutting initiatives, could help it bounce back. Merck could move beyond Keytruda thanks to newer approvals and a novel formulation of the medicine. Both companies have increased their dividends at a decent rate over the past five years. 10 stocks we like better than Pfizer › Dividend stocks are a great investment choice for many reasons. Buying on the dip is even better, provided, of course, they have the means to bounce back. Investors looking for companies that fit this profile should strongly consider Pfizer (NYSE: PFE) and Merck (NYSE: MRK). These two market leaders have lagged broader equities over the trailing-12-month period, but for those focused on the long game, they still look attractive. Here's the rundown. 1. Pfizer Over the past few years, Pfizer has dealt with worsening financial results and stiff competition for some products. It also faces the prospect of losing patent protection for others; these include Eliquis, an anticoagulant that is one of its top-selling drugs, and Xtandi, a cancer treatment. Both will lose their patents in the U.S. within the next few years. These challenges have led to terrible stock-market performance. However, the sell-off may have gone too far. At current levels, Pfizer's shares look attractive. One reason the company should bounce back and continue to deliver strong returns over the long run is its deep pipeline, particularly in oncology, one of the largest therapeutic areas in the industry. Pfizer currently has five blockbuster cancer medicines, and plans to raise that number to eight by 2030. Pfizer has exciting candidates in other areas as well, and in recent years has earned approval for several new products. Though these aren't yet meaningfully contributing to its top-line growth, they should do so eventually as they earn label expansion. The company's vaccine for respiratory syncytial virus (RSV), Abrysvo, generated $143 million in sales in the second quarter, which isn't bad for a product approved in 2023. It also recently earned a label expansion in Europe for adults age 18 to 59 (it was previously indicated for those 60 and older). Pfizer should make progress with Abrysvo and other newer launches. The company has also been reducing expenses. These initiatives were likely partly responsible for Pfizer's earnings beat during the second quarter. Management intends to achieve $4.5 billion in net cost savings this year and pursue further reductions in the years ahead, efforts that should help improve profitability. Pfizer is a solid dividend stock. Its forward yield currently tops 7%, and the company has increased its payouts by 19.5% in the past five years. While the stock may take some time to recover, Pfizer could be an excellent long-term investment for income-seeking investors. 2. Merck Merck is facing several issues, none more important than increased competition for its best-selling drug, cancer medicine Keytruda, and an upcoming patent cliff in 2028 for the medicine. Also, the company's second-quarter results were not strong: Revenue declined by 2% year over year to $15.8 billion, while adjusted earnings per share declined by 7% to $2.13. However, there were some bright spots for the company. Most notably, Winrevair -- one of its newest launches, which earned approval last year -- reported sales of $336 million. Winrevair is a therapy for pulmonary arterial hypertension with a new mechanism of action. It should become a blockbuster relatively soon. Merck's business in animal health -- where it's one of the leaders -- also performed well, with sales from that segment rising by 11% year over year to $1.6 billion in the second quarter. Meanwhile, Merck has some exciting pipeline candidates that should help it overcome Keytruda-related challenges. One of them is a subcutaneous version of Keytruda, which has already aced phase 3 studies and will help extend the medicine's patent protection. Merck has also significantly improved its pipeline in recent years thanks to licensing agreements. Its candidates include promising cancer products and weight loss medicines. Just as Winrevair appears to be a major success, Merck is also likely to develop innovative therapies that will mitigate potential Keytruda-related revenue losses. So, despite recent setbacks, the business could bounce back given Merck's history of innovation. Turning to Merck's dividend program, the company now offers a forward yield of 4.1%, with its dividends increasing by 39% over the past five years. The stock remains a good pick for dividend seekers. Should you invest $1,000 in Pfizer right now? Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025
Globe and Mail
an hour ago
- Globe and Mail
WKHS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Workhorse Group Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Workhorse Group Inc. (NASDAQ: WKHS) and Motiv Electric Trucks is fair to Workhorse shareholders. Upon completion of the proposed transaction, Workhorse shareholders will own approximately 26.5% of the combined company. Halper Sadeh encourages Workhorse shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@ or zhalper@ The investigation concerns whether Workhorse and its board violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Workhorse shareholders; and (2) disclose all material information necessary for Workhorse shareholders to adequately assess and value the merger consideration. On behalf of Workhorse shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits. We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors. Attorney Advertising. Prior results do not guarantee a similar outcome.
